Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT Study of ETX2514 in Healthy Volunteers
NCT03985410Phase 1Completed
- Sponsor
- Entasis Therapeutics
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of durlobactam in Acinetobacter baumannii-calcoaceticus complex infection (6 arms), sponsored by Entasis Therapeutics. Primary endpoint: Placebo-corrected change from Baseline in Fridericia-corrected QTc at Day 22. Started May 2019; status: completed.
02
Drugs
durlobactam
03
Conditions
Acinetobacter baumannii-calcoaceticus complex infection
Beyond the preview
Go deeper on NCT03985410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985410.